

Claims

1. The use of an agent for stimulating an immune response against a cancer and a chemotherapeutic drug, in the manufacture of a medicament for the treatment of said cancer wherein said drug is for administration in a metronomic schedule.
5
2. The use as claimed in claim 1, wherein the drug is for administration in a range from continuous fusion to weekly, without break.
- 10 3. The use as claimed in claim 2, wherein the drug is for administration in a range of 1-3 times a week.
4. The use as claimed in any preceding claim, wherein the drug is selected from cyclophosphamide, vinblastine, 5-fluorocil, 6-mercaptopurine, doxorubicin, taxol, cisplatin, etoposide, carboplatin, paclitaxel and topotecan.
15
5. The use as claimed in claim 4, wherein the drug is cyclophosphamide for administration at a dose of 130-250 mg/kg every 1-8 days.
- 20 6. The use as claimed in claim 5, wherein the cyclophosphamide is for administration at a dose of 175 mg/kg every 6 days.
7. The use as claimed in claim 4, wherein the drug is vinblastine for administration at a dose of 0.5-5 mg/kg every 1-7 days.
25
8. The use as claimed in claim 7, wherein the vinblastine is for administration at a dose of 1 mg/kg twice weekly.
9. The use as claimed in any preceding claim, wherein the agent for stimulating an immune response against said cancer comprises a tumour-specific antigen and/or nucleic acid encoding such an antigen.
30

10. The use as claimed in any preceding claim, wherein the agent for stimulating an immune response against said cancer comprises a plurality of tumour-specific antigens and/or nucleic acid encoding such antigens.

5 11. The use as claimed in claim 9 or claim 10, wherein the nucleic acid is in a suitable vector.

12. The use as claimed in claim 11, wherein the agent comprises different vectors comprising said nucleic acid.

10

13. The use as claimed in claim 12, wherein the agent comprises a recombinant DNA vector and a replication-impaired pox virus.

15

14. The use as claimed in claim 9, wherein the antigen is carried by dendritic cells.

15. The use as claimed in any preceding claim, wherein the agent for stimulating an immune response is for administration before the drug.

20

16. A product containing an agent for stimulating an immune response against a cancer; and a chemotherapeutic drug as a combined preparation for simultaneous, sequential or separate use in treating said cancer, the drug being for administration in a metronomic schedule.

25

17. A product as claimed in claim 16, modified by the features of any one of claims 2-15.

30

18. A method of treating a patient suffering from cancer, comprising administering to the patient:

an agent for stimulating an immune response against said cancer; and

a chemotherapeutic drug;

wherein said drug is administered in a metronomic schedule.

19. A method as claimed in claim 18, modified by the features of any one of claims 2-15.